Resalis Therapeutics

Resalis Therapeutics’ transformative metabolic disease approach targets MIR-22 which is a master regulator of multiple pathways underlying obesity and fatty liver disease.

The company is applying its understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable fat loss and reduction of hepatic steatosis. Building on robust preclinical evidence, Resalis will with the most recent funding bring RES-010 into clinical trials.

For more information, please contact:

Claus Andersson, PhD

General Partner

Phone: +45 2270 5065